Hemostatic Composition via Catheter Tract for Distant Vascular Puncture Sealing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hemostatic compositions and devices are ineffective in treating vascular complications such as hematomas and pseudoaneurysms associated with catheterization procedures, as they require invasive application and often fail to address punctures at a distance from the skin surface, leading to prolonged bleeding and increased risk of complications.
Innovation Solution
A method involving the topical application of a composition comprising a vasoconstrictor or coagulant, excluding poly-β-1→4 N-acetylglucosamine polymers or derivatives, in conjunction with compression to the affected vein or artery, allowing for rapid cessation or reduction of blood flow without direct contact with the puncture site, thereby reducing the occurrence of localized vascular complications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hemostatic patches are applied to seal skin puncture wounds, then the skin wound is sealed, but the underlying arterial puncture continues to bleed and localized vascular complications occur
Solution Approach 1:
The patent introduces a catheter tract as an intermediary pathway to deliver the hemostatic composition directly to the arterial puncture site. The composition travels through the catheter tract from the skin surface to the underlying artery, enabling targeted treatment without direct surgical access to the puncture site. This resolves the contradiction by making the treatment process easier while maintaining high hemostasis effectiveness.
2Reliability
If compression is applied to achieve hemostasis, then bleeding is controlled, but patients experience pain and require prolonged immobilization for 4-8 hours
Solution Approach 1:
The patent applies hemostatic composition to the catheter tract before removing the catheter, allowing the composition to be in place and ready to act immediately when the artery punctures after catheter removal. This preliminary application enables faster hemostasis (reducing immobilization time) while still achieving reliable bleeding control through the combined action of compression and the pre-positioned hemostatic agents.
3Reliability
If invasive procedures are used to treat arterial punctures, then direct access to the puncture site is achieved, but the risk of infection and additional tissue damage increases
Solution Approach 1:
The catheter tract serves as a sterile intermediary pathway that allows the hemostatic composition to reach the arterial puncture site without requiring invasive surgical procedures. The composition is delivered through the existing catheter pathway, minimizing the introduction of external contaminants and reducing infection risk while maintaining effective treatment of the arterial puncture.
4Reliability
If chitosan or chitin derivatives are used as hemostatic agents, then clotting is promoted, but the composition cannot effectively treat punctures at a distance from the skin surface
Solution Approach 1:
The catheter tract acts as a delivery conduit that overcomes the limitation of topical hemostatic agents. By introducing the chitosan-containing composition through the catheter tract, the patent enables the hemostatic agents to reach the arterial puncture site at a distance from the skin surface, combining the clotting-promoting properties of chitosan with the ability to treat deep vascular punctures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves a significant reduction in hemostasis time and incidence of vascular complications by effectively sealing breaches or punctures at a distance, with a 10-50% greater rate of blood flow cessation and 10-50% less time compared to conventional methods, while minimizing the risk of hematoma formation and invasive procedures.
Implementation Method 1
a composition comprising an effective amount of a vasoconstrictor, wherein the vasoconstrictor does not comprise a poly-β-1→4 N-acetylglucosamine polymer or derivative
Implementation Method 2
The hemostatic compositions can comprise one or more vasoconstrictors or one or more coagulants, or a combination of one or more vasoconstrictors with one or more coagulants
Data Source
AI summary
The present invention relates generally to the field of hemostasis, including methods, compositions, and devices that can be employed to achieve hemostasis at an increased rate. More specifically the present invention relates to hemostatic compositions that achieve a hemostatic effect at a distance from the site of application of the composition, and a method for administering such a composition to effectively reduce localized vascular complications associated with treating a breach or puncture in a vein or artery and reduce the time to achieve hemostasis.